Home > Current

PVSRIPO, A Potential New Tool in Our Fight against GBM

Jack Korleski （ Hugo W. Moser Research Institute at Kennedy Krieger ）

Hernando Lopez-Bertoni （ Hugo W. Moser Research Institute at Kennedy Krieger ）

https://doi.org/10.37155/2717-5278-0301-4

Abstract

GBM is the most common primary malignant brain cancer. Standard of care therapy includes maximum total resection with adjuvant radiation and chemotherapy with temozolomide[1]. GBM inevitably recurs and options to treat recurrent GBM are limited to resection of bulk tumor surgeries, radiation, and experimental targeted therapies. Despite these treatment options the median survival remains poor at 15 months[2]. Given the poor prognosis, new therapies are needed to expand the arsenal of treatment options for GBM.

One area of ongoing interest for cancer management is the use of oncolytic viruses as therapeutic modalities[3]. This class of viruses specifically target neoplastic cells and can eliminate them by different mechanisms, including induction of cell death via direct cellular toxicity, induction of tumor autoimmunity, or can be engineered to deliver high doses of chemotherapy[3,4]. In the context of GBM, a number of viruses are being studied for therapeutic development. Many of these include viruses known to target the CNS, such a poliovirus, HSV, measles and adenovirus[3,4]. Of these, PVSRIPO, a modified poliovirus has shown clinical potential in recent clinical trials[5,6].

Keywords

PVSRIPO; GBM

Full Text

PDF

References

Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol 22, iv1-iv96, doi:10.1093/neuonc/noaa200 (2020).
[2]. Cruz Da Silva, E., Mercier, M. C., Etienne-Selloum, N., Dontenwill, M. & Choulier, L. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers (Basel) 13, doi:10.3390/cancers13081795 (2021).
[3]. Haseley, A., Alvarez-Breckenridge, C., Chaudhury, A. R. & Kaur, B. Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov 4, 1-13, doi:10.2174/157488909787002573 (2009).
[4]. Martikainen, M. & Essand, M. Virus-Based Immunotherapy of Glioblastoma. Cancers (Basel) 11, doi:10.3390/cancers11020186 (2019).
[5]. Carpenter, A. B., Carpenter, A. M., Aiken, R. & Hanft, S. Oncolytic virus in gliomas: a review of human clinical investigations. Ann Oncol, doi:10.1016/j.annonc.2021.03.197 (2021).
[6]. Desjardins, A. et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med 379, 150-161, doi:10.1056/NEJMoa1716435 (2018).
[7]. De Jesus, N. H. Epidemics to eradication: the modern history of poliomyelitis. Virol J 4, 70, doi:10.1186/1743-422X-4-70 (2007).
[8]. Gromeier, M., Alexander, L. & Wimmer, E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A 93, 2370-2375, doi:10.1073/pnas.93.6.2370 (1996).
[9]. Chandramohan, V. et al. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Arch Pathol Lab Med 141, 1697-1704, doi:10.5858/arpa.2016-0580-OA (2017).
[10]. Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H. & Wimmer, E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 97, 6803-6808, doi:10.1073/pnas.97.12.6803 (2000).
[11]. Dobrikova, E. Y. et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther 16, 1865-1872, doi:10.1038/mt.2008.184 (2008).
[12]. Brown, M. C. et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 9, doi:10.1126/scitranslmed.aan4220 (2017).
[13]. Haumann, R., Videira, J. C., Kaspers, G. J. L., van Vuurden, D. G. & Hulleman, E. Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors. CNS Drugs 34, 1121-1131, doi:10.1007/s40263-020-00766-w (2020).
[14]. Friedman, G. K. et al. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 384, 1613-1622, doi:10.1056/NEJMoa2024947 (2021).

Copyright © 2021 Jack Korleski, Hernando Lopez-Bertoni Creative Commons License Publishing time:2021-06-30
This work is licensed under a Creative Commons Attribution 4.0 International License